Sjogrens Syndrome Market, 2012 to 2023
Market Outline: Sjogrens Syndrome Market
Sjogrens syndrome is an immune disorder which is indicated by two common symptoms dry mouth and dry eyes. Sometimes sjogrens syndromes are associated with other immune disorders like rheumatoid arthritis and lupus. In this condition mucous membrane of mouth and eyes get affected, which results in decreased secretion of tears and saliva. Sjogrens disease can occur at any age, it is more common in women.
Market Dynamics: Sjogrens Syndrome Market
Growing incidence of sjogrens syndrome coupled with rising awareness the sjogrens syndrome are expected to drive the growth of sjogrens syndrome market. Furthermore, increase in patient pool with rheumatoid arthritis and lupus, environmental pollution, growing demand for the advanced treatments and therapies are expected to boost the growth of the sjogrens syndrome market. However, lack of awareness is a major drawback sjogrens syndrome market.
Market Scope: Sjogrens Syndrome Market
The Global Sjogrens Syndrome Market is classified on the basis of drug, type, end user, and geographical regions.
Based on drug, global sjogrens syndrome market is segmented as
Pilocarpine
Cyclosporine
NSAIDS
Hydroxychloroquine
Based on the type, global sjogrens syndrome market is segmented as
Primary Sjogrens Syndrome
Secondary Sjogrens Syndrome
Based on the End User, global sjogrens syndrome market is segmented as
Hospitals
Clinics
Pharmacies
Online pharmacies
Region Overview: Sjogrens Syndrome Market
Strong pipeline for sjogrens syndrome, high R&D investments are expected to create demand for sjogrens syndrome market. Market players are concentrated on new product innovations and launches, partnerships and collaborations, mergers and acquisitions in order to strengthen presence and product portfolio. For example, in 2014, Nicox SA launched Xailin and AdenoPlus and in June 2015, Allergen acquired Oculeve Inc to enhance its novel technologies for dry eye.
Global sjogrens syndrome market is segmented into Latin America, North America, Asia Pacific, The Middle East and Africa and Europe. North America followed by Europe holds the largest share in global sjogrens syndrome market owing to growing geriatric population, advanced healthcare system, high adoption of technological advancements. Asia Pacific region is anticipated to show rapid growth in sjogrens syndrome market owing to rise in awareness regarding the disorder, large population pool, rise in disposable income, developing healthcare infrastructure.
Competition Assessment: Sjogrens Syndrome Market
Some of the players in global sjogrens syndrome market
Allergan Inc. (Ireland)
Auven Therapeutics (U.S.)
Novartis AG (Switzerland)
Santen Pharmaceutical Co. Ltd. (Japan)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Argentis Pharmaceuticals, LLC. (UK)
Nicox S.A. (France)
Key Developments
In October 2015, Allergan introduced synthetic tears REFRESH OPTIVE gel drops to relieve dry eye symptoms.
In November 2013, Nicox SA introduced advanced diagnostic panel for detection of sjogrens syndrome in early stages in U.S.
Sjogrens syndrome is an immune disorder which is indicated by two common symptoms dry mouth and dry eyes. Sometimes sjogrens syndromes are associated with other immune disorders like rheumatoid arthritis and lupus. In this condition mucous membrane of mouth and eyes get affected, which results in decreased secretion of tears and saliva. Sjogrens disease can occur at any age, it is more common in women.
Market Dynamics: Sjogrens Syndrome Market
Growing incidence of sjogrens syndrome coupled with rising awareness the sjogrens syndrome are expected to drive the growth of sjogrens syndrome market. Furthermore, increase in patient pool with rheumatoid arthritis and lupus, environmental pollution, growing demand for the advanced treatments and therapies are expected to boost the growth of the sjogrens syndrome market. However, lack of awareness is a major drawback sjogrens syndrome market.
Market Scope: Sjogrens Syndrome Market
The Global Sjogrens Syndrome Market is classified on the basis of drug, type, end user, and geographical regions.
Based on drug, global sjogrens syndrome market is segmented as
Pilocarpine
Cyclosporine
NSAIDS
Hydroxychloroquine
Based on the type, global sjogrens syndrome market is segmented as
Primary Sjogrens Syndrome
Secondary Sjogrens Syndrome
Based on the End User, global sjogrens syndrome market is segmented as
Hospitals
Clinics
Pharmacies
Online pharmacies
Region Overview: Sjogrens Syndrome Market
Strong pipeline for sjogrens syndrome, high R&D investments are expected to create demand for sjogrens syndrome market. Market players are concentrated on new product innovations and launches, partnerships and collaborations, mergers and acquisitions in order to strengthen presence and product portfolio. For example, in 2014, Nicox SA launched Xailin and AdenoPlus and in June 2015, Allergen acquired Oculeve Inc to enhance its novel technologies for dry eye.
Global sjogrens syndrome market is segmented into Latin America, North America, Asia Pacific, The Middle East and Africa and Europe. North America followed by Europe holds the largest share in global sjogrens syndrome market owing to growing geriatric population, advanced healthcare system, high adoption of technological advancements. Asia Pacific region is anticipated to show rapid growth in sjogrens syndrome market owing to rise in awareness regarding the disorder, large population pool, rise in disposable income, developing healthcare infrastructure.
Competition Assessment: Sjogrens Syndrome Market
Some of the players in global sjogrens syndrome market
Allergan Inc. (Ireland)
Auven Therapeutics (U.S.)
Novartis AG (Switzerland)
Santen Pharmaceutical Co. Ltd. (Japan)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Argentis Pharmaceuticals, LLC. (UK)
Nicox S.A. (France)
Key Developments
In October 2015, Allergan introduced synthetic tears REFRESH OPTIVE gel drops to relieve dry eye symptoms.
In November 2013, Nicox SA introduced advanced diagnostic panel for detection of sjogrens syndrome in early stages in U.S.
1. EXECUTIVE SUMMARY
2. GLOBAL SJOGRENS SYNDROME MARKET INTRODUCTION
2.1. Global Sjogrens Syndrome Market – Taxonomy
2.2. Global Sjogrens Syndrome Market –Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. GLOBAL SJOGRENS SYNDROME MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Sjogrens Syndrome Market Dynamics – Factors Impact Analysis
3.6. Global Sjogrens Syndrome Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Sjogrens Syndrome Market – Product Innovations
4. GLOBAL SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL SJOGRENS SYNDROME MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Pilocarpine
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Cyclosporine
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. NSAID’s
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Hydroxychloroquine
5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
6. GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Primary Sjogrens Syndrome
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Secondary Sjogrens Syndrome
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
7. MARKET OPPORTUNITY ANALYSIS GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Disease Type, Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Pilocarpine
9.1.1.2. Cyclosporine
9.1.1.3. NSAIDS
9.1.1.4. Hydroxychloroquine
9.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Primary Sjogrens Syndrome
9.1.2.2. Secondary Sjogrens Syndrome
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Disease, Distribution Channel and Country, 2017 – 2023
9.1.6. North America Sjogrens Syndrome Market Dynamics – Trends
10. EUROPE SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Pilocarpine
10.1.1.2. Cyclosporine
10.1.1.3. NSAIDS
10.1.1.4. Hydroxychloroquine
10.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Primary Sjogrens Syndrome
10.1.2.2. Secondary Sjogrens Syndrome
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Others
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Sjogrens Syndrome Market Dynamics – Trends
11. ASIA-PACIFIC SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Pilocarpine
11.1.1.2. Cyclosporine
11.1.1.3. NSAIDS
11.1.1.4. Hydroxychloroquine
11.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Primary Sjogrens Syndrome
11.1.2.2. Secondary Sjogrens Syndrome
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
11.1.6. Europe Sjogrens Syndrome Market Dynamics – Trends
12. LATIN AMERICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Pilocarpine
12.1.1.2. Cyclosporine
12.1.1.3. NSAIDS
12.1.1.4. Hydroxychloroquine
12.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Primary Sjogrens Syndrome
12.1.2.2. Secondary Sjogrens Syndrome
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Sjogrens Syndrome Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Pilocarpine
13.1.1.2. Cyclosporine
13.1.1.3. NSAIDS
13.1.1.4. Hydroxychloroquine
13.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Primary Sjogrens Syndrome
13.1.2.2. Secondary Sjogrens Syndrome
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Sjogrens Syndrome Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.3. Allergan Inc. (Ireland)
14.4. Auven Therapeutics (U.S.)
14.5. Novartis AG (Switzerland)
14.6. Santen Pharmaceutical Co. Ltd. (Japan)
14.7. Otsuka Pharmaceutical Co., Ltd. (Japan)
14.8. Argentis Pharmaceuticals, LLC. (UK)
14.9. Nicox S.A. (France)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL SJOGRENS SYNDROME MARKET INTRODUCTION
2.1. Global Sjogrens Syndrome Market – Taxonomy
2.2. Global Sjogrens Syndrome Market –Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. GLOBAL SJOGRENS SYNDROME MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Sjogrens Syndrome Market Dynamics – Factors Impact Analysis
3.6. Global Sjogrens Syndrome Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Sjogrens Syndrome Market – Product Innovations
4. GLOBAL SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL SJOGRENS SYNDROME MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Drug Class Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
5.1.1. Pilocarpine
5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Cyclosporine
5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. NSAID’s
5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Hydroxychloroquine
5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
6. GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Primary Sjogrens Syndrome
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Secondary Sjogrens Syndrome
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
7. MARKET OPPORTUNITY ANALYSIS GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. GLOBAL SJOGRENS SYNDROME MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Disease Type, Distribution Channel, and Region, 2017 – 2023
9. NORTH AMERICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Pilocarpine
9.1.1.2. Cyclosporine
9.1.1.3. NSAIDS
9.1.1.4. Hydroxychloroquine
9.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Primary Sjogrens Syndrome
9.1.2.2. Secondary Sjogrens Syndrome
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Disease, Distribution Channel and Country, 2017 – 2023
9.1.6. North America Sjogrens Syndrome Market Dynamics – Trends
10. EUROPE SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Pilocarpine
10.1.1.2. Cyclosporine
10.1.1.3. NSAIDS
10.1.1.4. Hydroxychloroquine
10.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Primary Sjogrens Syndrome
10.1.2.2. Secondary Sjogrens Syndrome
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Others
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Sjogrens Syndrome Market Dynamics – Trends
11. ASIA-PACIFIC SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Pilocarpine
11.1.1.2. Cyclosporine
11.1.1.3. NSAIDS
11.1.1.4. Hydroxychloroquine
11.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Primary Sjogrens Syndrome
11.1.2.2. Secondary Sjogrens Syndrome
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
11.1.6. Europe Sjogrens Syndrome Market Dynamics – Trends
12. LATIN AMERICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Pilocarpine
12.1.1.2. Cyclosporine
12.1.1.3. NSAIDS
12.1.1.4. Hydroxychloroquine
12.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Primary Sjogrens Syndrome
12.1.2.2. Secondary Sjogrens Syndrome
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Sjogrens Syndrome Market Dynamics – Trends
13. MIDDLE EAST AND AFRICA SJOGRENS SYNDROME MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Pilocarpine
13.1.1.2. Cyclosporine
13.1.1.3. NSAIDS
13.1.1.4. Hydroxychloroquine
13.1.2. Disease Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Primary Sjogrens Syndrome
13.1.2.2. Secondary Sjogrens Syndrome
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Sjogrens Syndrome Market - Opportunity Analysis Index, By Drug Class, Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Sjogrens Syndrome Market Dynamics – Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.3. Allergan Inc. (Ireland)
14.4. Auven Therapeutics (U.S.)
14.5. Novartis AG (Switzerland)
14.6. Santen Pharmaceutical Co. Ltd. (Japan)
14.7. Otsuka Pharmaceutical Co., Ltd. (Japan)
14.8. Argentis Pharmaceuticals, LLC. (UK)
14.9. Nicox S.A. (France)
15. RESEARCH METHODOLOGY
16. KEY ASSUMPTIONS AND ACRONYMS
